Safety of concomitant therapy with radium‐223 and abiraterone or enzalutamide in a real‐world population

Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.

(2020) Neeraj Agarwal et al.   CLINICAL CANCER RESEARCH

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Matthew Smith et al.   LANCET ONCOLOGY

Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.

(2019) Bertrand F. Tombal et al.   JOURNAL OF CLINICAL ONCOLOGY

Early use of abiraterone and radium-223 in metastatic prostate cancer

(2019) Maria Concetta Cursano et al.   LANCET ONCOLOGY

Radium-223 mechanism of action: implications for use in treatment combinations

(2019) Michael J. Morris et al.   Nature Reviews Urology

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

(2018) Philipp Nuhn et al.   EUROPEAN UROLOGY

Metastatic Prostate Cancer

(2018) Oliver Sartor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

(2017) Oliver Sartor et al.   ONCOLOGIST

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

(2016) Fred Saad et al.   LANCET ONCOLOGY

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment

(2015) Michele Iuliani et al.   Oncotarget

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY